Visipaque is a Intravascular Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Ge Healthcare Inc.. The primary component is Iodixanol.
Product ID | 0407-2223_0a22bcdf-5055-4a51-a515-65926207ccb4 |
NDC | 0407-2223 |
Product Type | Human Prescription Drug |
Proprietary Name | Visipaque |
Generic Name | Iodixanol |
Dosage Form | Injection, Solution |
Route of Administration | INTRAVASCULAR |
Marketing Start Date | 2010-06-01 |
Marketing Category | NDA / NDA |
Application Number | NDA020351 |
Labeler Name | GE Healthcare Inc. |
Substance Name | IODIXANOL |
Active Ingredient Strength | 320 mg/mL |
Pharm Classes | Radiographic Contrast Agent [EPC],X-Ray Contrast Activity [MoA] |
NDC Exclude Flag | N |
Listing Certified Through | 2021-12-31 |
Marketing Start Date | 2010-06-01 |
NDC Exclude Flag | N |
Sample Package? | N |
Marketing Category | NDA |
Application Number | NDA020351 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2010-06-01 |
Marketing End Date | 2015-05-21 |
Marketing Category | NDA |
Application Number | NDA020351 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2003-09-09 |
Marketing Category | NDA |
Application Number | NDA020351 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2003-09-09 |
Marketing End Date | 2015-11-29 |
Marketing Category | NDA |
Application Number | NDA020351 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 2003-09-09 |
Marketing End Date | 2012-04-20 |
Marketing Category | NDA |
Application Number | NDA020351 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2003-09-09 |
Marketing Category | NDA |
Application Number | NDA020351 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2010-06-01 |
Marketing Category | NDA |
Application Number | NDA020351 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 2003-09-09 |
Marketing End Date | 2019-04-11 |
Marketing Category | NDA |
Application Number | NDA020351 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2003-09-09 |
Marketing Category | NDA |
Application Number | NDA020351 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 2003-09-09 |
Marketing End Date | 2012-04-20 |
Marketing Category | NDA |
Application Number | NDA020351 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 2003-09-09 |
Marketing End Date | 2019-04-12 |
Marketing Category | NDA |
Application Number | NDA020808 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2006-05-01 |
Marketing Category | NDA |
Application Number | NDA020351 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2003-09-09 |
Marketing End Date | 2012-04-20 |
Marketing Category | NDA |
Application Number | NDA020351 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2003-09-09 |
Marketing End Date | 2015-10-10 |
Marketing Category | NDA |
Application Number | NDA020351 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2010-06-01 |
Marketing End Date | 2015-05-21 |
Marketing Category | NDA |
Application Number | NDA020351 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2003-09-09 |
Marketing End Date | 2018-07-28 |
Marketing Category | NDA |
Application Number | NDA020351 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2003-09-09 |
Marketing End Date | 2016-01-24 |
Marketing Category | NDA |
Application Number | NDA020351 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2010-06-01 |
Marketing Category | NDA |
Application Number | NDA020351 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2003-09-09 |
Marketing Category | NDA |
Application Number | NDA020351 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2010-06-01 |
Marketing Category | NDA |
Application Number | NDA020351 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 2003-09-09 |
Marketing End Date | 2019-03-25 |
Marketing Category | NDA |
Application Number | NDA020351 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2010-06-01 |
Marketing End Date | 2015-05-21 |
Marketing Category | NDA |
Application Number | NDA020351 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 2003-09-09 |
Marketing End Date | 2012-04-20 |
Marketing Category | NDA |
Application Number | NDA020351 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2003-09-09 |
Marketing End Date | 2015-12-14 |
Marketing Category | NDA |
Application Number | NDA020351 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2003-09-09 |
Marketing Category | NDA |
Application Number | NDA020351 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 2003-09-09 |
Marketing End Date | 2015-11-29 |
Marketing Category | NDA |
Application Number | NDA020351 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2010-06-01 |
Marketing Category | NDA |
Application Number | NDA020351 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 2003-09-09 |
Marketing End Date | 2015-08-31 |
Marketing Category | NDA |
Application Number | NDA020808 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 2006-05-01 |
Marketing End Date | 2017-08-18 |
Marketing Category | NDA |
Application Number | NDA020351 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 2003-09-09 |
Marketing End Date | 2012-04-20 |
Marketing Category | NDA |
Application Number | NDA020351 |
Product Type | HUMAN PRESCRIPTION DRUG |
Marketing Start Date | 2003-09-09 |
Marketing End Date | 2015-09-26 |
Marketing Category | NDA |
Application Number | NDA020351 |
Product Type | HUMAN PRESCRIPTION DRUG |
Billing Unit | ML |
Marketing Start Date | 2010-06-01 |
Marketing End Date | 2015-05-21 |
Ingredient | Strength |
---|---|
IODIXANOL | 320 mg/mL |
SPL SET ID: | 952d0aa5-6dfd-49cc-8476-b781e5c7b86c |
Manufacturer | |
UNII |
NDC | Brand Name | Generic Name |
---|---|---|
0407-2222 | Visipaque | Iodixanol |
0407-2223 | Visipaque | Iodixanol |
65219-381 | Iodixanol | Iodixanol |
65219-383 | Iodixanol | Iodixanol |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
VISIPAQUE 74448170 not registered Dead/Abandoned |
Sterling Winthrop Inc. 1993-10-18 |
VISIPAQUE 74085163 1726942 Live/Registered |
GE HEALTHCARE AS 1990-08-06 |